Our leading subject matter experts share their insightful analysis and points of view to help you stay abreast of industry trends
Pharma manufacturers invest significant time and money developing resources for payers, from budget impact models to PIE packages and NCCN summaries. But are those resources hitting the mark?
New Q1…
After years of record growth driven by subsidized premiums, enrollment in Affordable Care Act (ACA) exchange plans plummeted this year from its all-time high of 24.3 million members in 2025.…
For many manufacturers, the period between FDA submission and the PDUFA date feels deceptively quiet. Clinical work is largely complete, pricing assumptions have already been modeled, and commercial teams are…
When the Inflation Reduction Act (IRA) first passed in late 2022, payers rushed to respond. On paper, the bill’s intentions were clear: this legislation sought to lower drug costs, reduce…
Copay accumulator and maximizer programs are now firmly embedded in the commercial market, and their influence on patient access and manufacturer strategy is becoming impossible to overlook. In the first…
As payers continue to refine their cost-containment strategies, copay accumulator and copay maximizer programs have quietly become standard tools in their playbook. Despite recent legislation, the majority of payers are…
The mental health treatment landscape is evolving rapidly, driven by new and innovative therapies. Recent approvals like KarXT (from Karuna Therapeutics, now part of Bristol Myers Squibb) for schizophrenia, as…
Transthyretin amyloidosis (ATTR) has rapidly shifted from a rarely recognized, fatal condition into one of the most closely watched rare-disease markets in biopharma.
With multiple therapeutic entrants, distinct scientific platforms,…
In July 2025, the 2025 Federal Budget Reconciliation bill, known colloquially as the One Big Beautiful Bill Act (OBBBA) and officially as H.R.1, was signed into law.
This act introduced…
Urinary tract infections (UTIs) rank as the most common bacterial infection for women worldwide. Between 50-60% of adult women experience at least one UTI in their lifetime, and approximately 25%…
